Echo Therapeutics (Echo Therapeutics) Beneish M-Score : 0.00 (As of May. 11, 2024)

View and export this data going back to 1997. Start your Free Trial

What is Echo Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Echo Therapeutics's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Echo Therapeutics was 0.00. The lowest was 0.00. And the median was 0.00.

Echo Therapeutics Beneish M-Score Historical Data

The historical data trend for Echo Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Echo Therapeutics Beneish M-Score Chart

Echo Therapeutics Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Beneish M-Score

Get a 7-Day Free Trial

-3.07

-26.13

1.18

-2.14

-81.76

Echo Therapeutics Quarterly Data
	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Beneish M-Score	Get a 7-Day Free Trial															-87.76	-81.76	-63.93	-6.16	-10.63

Competitive Comparison of Echo Therapeutics's Beneish M-Score

For the Medical Devices subindustry, Echo Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Echo Therapeutics's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Echo Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Echo Therapeutics's Beneish M-Score falls into.

Echo Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Echo Therapeutics for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Sep16) TTM:

Last Year (Sep15) TTM:

Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $0.40 Mil.
Total Assets was $1.08 Mil.
Property, Plant and Equipment(Net PPE) was $0.19 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.12 Mil.
Selling, General, & Admin. Expense(SGA) was $3.44 Mil.
Total Current Liabilities was $7.27 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was 0.794 + -2.941 + -2.621 + -1.276 = $-6.04 Mil.
Non Operating Income was 2.741 + -1.347 + -0.926 + 0.143 = $0.61 Mil.
Cash Flow from Operations was -0.861 + -1.494 + -1.812 + -0.648 = $-4.82 Mil.

Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $0.23 Mil.
Total Assets was $0.77 Mil.
Property, Plant and Equipment(Net PPE) was $0.30 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.58 Mil.
Selling, General, & Admin. Expense(SGA) was $6.00 Mil.
Total Current Liabilities was $2.53 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(0 / 0)	/	(0 / 0)
	=		/
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0 / 0)	/	(0 / 0)
	=		/
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (0.402 + 0.189) / 1.077)	/	(1 - (0.227 + 0.302) / 0.765)
	=	0.451253	/	0.308497
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0	/	0
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.584 / (0.584 + 0.302))	/	(0.12 / (0.12 + 0.189))
	=	0.659142	/	0.38835
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(3.438 / 0)	/	(6.004 / 0)
	=		/
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0 + 7.267) / 1.077)	/	((0 + 2.532) / 0.765)
	=	6.747447	/	3.309804
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-6.044 - 0.611	-	-4.815)	/	1.077
	=	-1.708449

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Echo Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Echo Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Echo Therapeutics (Echo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Echo Therapeutics Inc (OTCPK:ECTE) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

99 Wood Avenue South, Suite 302, Iselin, NJ, USA, 08830

Website

http://www.echotx.com

Echo Therapeutics Inc is a medical device company with expertise in skin permeation technology. It develops non-invasive, wireless continuous glucose monitoring system with potential use in the wearable health consumer and the diabetes outpatient market.

Executives

Michael M Goldberg	director	C/O MONTAUR CAPITAL PARTNERS, 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Uri Landesman	10 percent owner	230 PARK AVENUE, NEW YORK NY 10169
Platinum Partners Value Arbitrage Fund, Lp	10 percent owner	250 WEST 55TH STREET, 14TH FLOOR, NEW YORK NY 10019
Mark Nordlicht	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Platinum Management (ny) Llc	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Platinum-montaur Life Sciences, Llc	10 percent owner	152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Partners Liquid Opportunity Master Fund L.p.	10 percent owner	152 WEST 57 STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Liquid Opportunity Management (ny) Llc	10 percent owner	152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Bernhardt Charles Thomas Iii	officer: Interim CFO	23 BIRCH ROAD, MALVERN PA 19355
Vincent D Enright	director	ONE CORPORATE CENTER, RYE NY 10580
William Grieco	director	830 CRESCENT CENTRE DRIVE, SUITE 610, FRANKLIN TN 37067
Platinum Long Term Growth Vii, Llc	10 percent owner	152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Robert F Doman	director, officer: EXEC. CHAIRMAN AND INTERIM CEO	C/O DUSA PHARMACEUTICALS, INC., 25 UPTON DRIVE, WILMINGTON MA 01887
Patrick T Mooney	director, officer: CEO AND PRESIDENT	C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Christopher P. Schnittker	officer: CFO	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540

Echo Therapeutics (Echo Therapeutics) Headlines

No Headlines